A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy (RESPONSE)
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RESPONSE
Most Recent Events
- 17 Mar 2020 New trial record